EIC Accelerator Winner FluoGuide and the Cancer Surgery Dye Race

Surgeons removing a brain tumour face a trade-off: cut too little and the cancer returns, cut too much and the patient may lose speech or movement. FluoGuide, a Copenhagen company built on research from Rigshospitalet and the University of Copenhagen, develops FG001, an intravenous dye that binds to a receptor called uPAR on cancer cells and glows under near-infrared light so that surgeons can see where a tumour ends. In the EIC Accelerator pilot's January 2020 cut-off it won an EU grant of €2,499,868.69 for INSTAGLOW, a €5,085,250.50 project to speed FG001 towards a phase IIb/III trial in glioblastoma, according to CORDIS.

Six years later FG001 has passed several phase II trials and the US Food and Drug Administration has cleared a US study, which enrolled its first patient on 5 October 2026, according to a company announcement and the trial site, the University of Texas Medical Branch. The revenue plan in the EIC application, with first sales in 2021, European sales in 2023 and a US and Asian roll-out in 2025, has not materialised: FluoGuide reported no revenue in 2025, according to its year-end report.

Where FluoGuide Stands Now

FluoGuide is an active, listed, clinical-stage company. North Data's copy of the Danish company register shows no insolvency or liquidation filings, a move to Titangade in January 2025 and annual accounts filed for every year to 2025. Those accounts, published by the Danish Business Authority, show an average of 6.7 employees in 2025, down from 7.8 in 2023 and 2024.

The current focus is the US. The FDA allowed the company to proceed with its first US trial on 20 February 2026, according to the company and CURE, and granted FG001 Fast Track designation in March 2026, according to CancerNetwork. FluoGuide expects that two US trials will be needed for approval in high-grade glioma, each enrolling over about a year. The first, FG001-CT-006, is a Phase 2 study in newly diagnosed WHO grade 3 or 4 glioma, with a dose of 0.45 mg/kg given 12 to 19 hours before surgery and six months of follow-up.

That trial started later than the company said it would. In February 2026 FluoGuide expected its first patient in the second quarter; on 1 July it said July 2026, according to its outlook update, also published on MFN. The first patient was enrolled on 5 October. The same update pushed topline results of its head and neck cancer trial from the second half of 2026 to the first half of 2027.

The Technology: A Dye That Targets uPAR

uPAR, the urokinase-type plasminogen activator receptor, is found on many solid tumours and is concentrated at the invasive edge where tumour meets healthy tissue, the company states in its CORDIS report. FG001 links a uPAR-binding peptide to a near-infrared fluorophore. Because it shares the spectral properties of indocyanine green, an approved dye, it can be used with existing surgical imaging equipment, as Targeted Oncology and Pharmaceutical Technology reported when the FDA granted the dye orphan drug designation in October 2023. The science comes from Professor Andreas Kjær's group at Rigshospitalet and the University of Copenhagen, according to a 2020 company release carried by BioSpace; Kjær was FluoGuide's first board chair, per North Data.

The established alternative in brain surgery is 5-ALA (Gleolan), an oral drug that makes glioma cells glow under blue light. The European Medicines Agency approved it in 2007 and the FDA in June 2017, after a phase III trial in which complete resection of the enhancing tumour rose from 36% to 65% of patients, according to a review in the Journal of Neuro-Oncology. Patients taking it must stay out of bright light for 48 to 72 hours afterwards, according to Henry Ford Health. Outside the brain, targeted dyes have also reached the market: the FDA approved On Target Laboratories' Cytalux for ovarian cancer surgery in 2021, according to Penn Today. FluoGuide's case rests on one agent working across many cancer types.

What INSTAGLOW Promised, and What the Record Shows

INSTAGLOW ran from 1 July 2020 to 31 December 2022. FluoGuide is its only beneficiary: the Commission's list of January 2020 winners names FluoGuide, Copenhagen N, with a grant-only award and no partner company. The EU paid less than half of the project's cost, and the company's 2021 year-end report, summarised by Börskollen, records a €750,000 tranche of the grant received that year.

The objective on CORDIS was explicit. The grant would "accelerate FG001's clinical phase IIb/III study for GBM", and the company would generate revenue through "direct sales for compassionate use sales (2021)", "direct sales in EU (2023)" and a "roll-out to US and Asia (2025)" through regional partners. The final report says FG001 was well tolerated in a high-grade glioma trial, with 100% specificity and 79% sensitivity against pathology; that a manufacturing process for commercial stage was developed; that a quality system was set up; and that clinical data were generated in grade III glioma, meningioma and lung cancer. The results page lists two deliverables, two papers and four patent applications. The EU's Horizon Magazine reported in September 2023 that the dye had been tested in 36 brain cancer patients in Denmark and Sweden and in 16 lung cancer patients.

1. Clinical safety and efficacy data in glioblastomaDeliveredPhase I/II data in the CORDIS report; phase IIb met its primary endpoint in November 2023, after the project closed.
2. Commercial-stage manufacturing and quality systemDeliveredReported as done in the CORDIS final report; no independent confirmation.
3. Phase III trial in glioblastomaNot achievedNot started; the first US Phase 2 patient was enrolled in October 2026.
4. Compassionate use sales, 2021Not achievedNo sales announced; no revenue in the accounts.
5. Direct sales in the EU, 2023Not achievedFG001 has no marketing approval in the EU.
6. US and Asia roll-out with partners, 2025Not achievedOnly non-exclusive device collaborations with no payments; no licensing deal.

The clinical work the EU paid for was done, and done reasonably fast for a team of three to eight people. The commercial timeline in the application was not realistic for an imaging drug that still needed late-stage trials, and none of its dates was met.

What FluoGuide Has Achieved Since the Award

The pipeline has broadened. FG001 met its primary endpoint in the 2023 brain cancer phase IIb and produced positive topline phase II results in lung cancer, according to the 2023 annual report as summarised by Inderes and Börskollen. In June 2026 the first part of a phase II trial in oral cancer identified 0.30 mg/kg as the optimal dose in 15 patients, according to News-Medical, which also reported that more than 125 patients have now received FG001. A second part with 10 more patients is planned.

FluoGuide has signed collaborations with three makers of surgical imaging systems: Olympus in July 2025 for head and neck cancer, as reported by Nordic Life Science; ZEISS in November 2025, per the year-end report; and Leica Microsystems on 2 October 2026 for brain surgery, according to the announcement on Placera. Each is non-exclusive and carries no initial payment. They show that device makers want their microscopes to work with the dye; they are not commercial licences.

The Money

FluoGuide has paid for its trials by selling shares. It listed on Spotlight in May 2019 with an offering of about DKK 15.9 million that was 244% subscribed, according to Spotlight Stock Market, and moved to Nasdaq First North on 24 February 2021, per Cision. In 2021 it raised SEK 75 million in a directed issue, according to its 2021 year-end report on Börskollen. In November 2025 it sold 2,729,164 new shares at SEK 38 each to Nordic institutional investors for SEK 104 million, according to MFN and Inderes. The same announcement says a SEK 40 million credit facility, extended to April 2027, is fully drawn; the lender is not named.

The 2025 accounts show a net loss of DKK 39.5 million, cash of DKK 48.8 million, equity of DKK 54.5 million and DKK 27.6 million of long-term borrowings from credit institutions, according to the annual report release, a second copy and the filed XBRL accounts. By 30 June 2026 equity had fallen to DKK 30.7 million after a half-year loss of DKK 24.6 million, with DKK 49.8 million in cash and securities, according to the Q2 report, also on MFN. The report gives no runway estimate, and the company has not said how it will pay for the two US trials and the phase III drug supply it plans.

Why Europe Should Care

The Commission's Europe's Beating Cancer Plan, adopted on 3 February 2021 with €4 billion of EU funding, covers the full path from prevention to treatment and sets a target of 90% of eligible patients having access to national comprehensive cancer centres by 2030, as Cancerworld also reported. More precise surgery fits that aim, and an imaging agent that works with microscopes from Olympus, ZEISS and Leica could reach hospitals without new equipment.

The strategic irony is that the first market FluoGuide is chasing for approval is the United States. The phase II data came from Danish and Swedish hospitals and the EU grant financed the trials, but the trial meant to support registration runs under a US IND. Whether a European marketing application follows has not been announced.

The Verdict

FluoGuide has not been asked for comment for this article. It is based entirely on public records, company announcements and EU project data, linked throughout.